Abstract
The aim of the study is to identify treatments which predict survival for women with a BRCA1 mutation, including oophorectomy and chemotherapy. 476 women with stage I to stage III breast cancer who carried a BRCA1 mutation were followed from diagnosis until April 2015. Information on treatment was obtained from chart review and patient questionnaires. Dates of death were obtained from the Poland vital statistics registry. Survival curves were compared for different subgroups according to treatment received. Predictors of overall survival were determined using the Cox proportional hazards model. The ten-year overall survival was 78.3 % (95 % CI 74.2–82.6 %) and the ten-year breast cancer-specific survival was 84.2 % (95 % CI 80.5–88.0 %). Sixty-two patients died of breast cancer, 14 patients died of ovarian cancer, and 2 patients died of peritoneal cancer. Oophorectomy was associated with a significant reduction in all-cause mortality in the entire cohort (adjusted HR = 0.41; 95 % CI 0.24–0.69; p = 0.0008) and in breast cancer-specific mortality among ER-negative breast cancer patients (HR = 0.44; 95 % CI 0.22–0.89; p = 0.02). Among women with breast cancer and a BRCA1 mutation, survival is greatly improved by oophorectomy due to the prevention of deaths from both breast and ovarian cancer.
Similar content being viewed by others
References
Collins FS, Varmus H (2015) A new initiative on precision medicine. N Engl J Med 372(9):793–795
Narod SA (2012) Breast cancer in young women. Nat Rev Clin Oncol 9(8):460–470
Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA (2015) Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 313(2):165–173
Byrski T, Gronwald J, Huzarski T et al (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375–379
Górski B, Jakubowska A, Huzarski T et al (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110:683–686
Rijnsburger AJ, Obdeijn IM, Kaas R et al (2010) BRCA1-associated breast cancers behave differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC study. J Clin Oncol 28:5265–5273
Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, Eisen A, Rosen B, Snyder C, Gershman S, Sun P, Narod SA (2015) Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol 1(3):306–313
Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, Kim-Sing C, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA (2014) Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 348:226
Narod SA, Metcalfe K, Lynch HT, Ghadirian P, Robidoux A, Tung N, Gaughan E, Kim-Sing C, Olopade OI, Foulkes WD, Robson M, Offit K, Jakubowska A, Byrski T, Huzarski T, Sun P, Lubinski J (2013) Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat 138(1):273–279
Goodwin PJ, Phillips KA, West DW et al (2012) Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers. An International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol 30:19–26
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Additional information
Other members of the Polish Hereditary Breast Cancer Consortium are listed in Appendix.
Appendix
Appendix
Bębenek M, Błasińska-Morawiec M, Breborowicz J, Chosia M, Drosik K, Dziuba I, Fudali L, Gozdecka-Grodecka S, Goźdź S, Grzybowska E, Haus O, Jeziorski A, Karczewska A, Kordek R, Kozak A, Kozłowski A, Lamperska K, Lange D, Mackiewicz A, J Menkiszak, Mituś J, Musiatowicz B, Niepsuj S, Rozmiarek A, Ryś J, Sibilski R, Sir J, Sorokin D, Sygut J, Szczylik C, Uciński M, Urbański K, Wachuła E, Waśko B, Wojnar A, Wandzel P.
Rights and permissions
About this article
Cite this article
Huzarski, T., Byrski, T., Gronwald, J. et al. The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 156, 371–378 (2016). https://doi.org/10.1007/s10549-016-3749-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-016-3749-4